Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: A prospective study from the GEL-TAMO study group

European Journal of Haematology

Volumn 80, Issue 3, 2008, Pages 227-235

  Arranz, Reyes ^a   Conde, Eulogio ^b   Grande, Carlos ^c   Mateos, Maria Victoria ^d   Gandarillas, Marco ^b   Albo, Carmen ^e   Lahuerta, Juan J ^b   Fernández Rañada, José M ^a   Hernández, Miguel T ^f   Alonso, Natalia ^g   García Vela, José A ^h   Garzón, Sebastián ⁱ   Rodríguez, José ^j   Caballero, Dolores ^d  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^e HOSPITAL XERAL CÍES   (Spain)

^f HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^g HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^h HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

ⁱ HOSPITAL DE JEREZ   (Spain)

^j HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

more..

Author keywords

Early response adapted treatment; High dose therapy with autologous stem cell support; Poor risk B aggressive non Hodgkin's lymphoma; Prospective

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; GALLIUM; GRANULOCYTE COLONY STIMULATING FACTOR; MESNA; PREDNISOLONE; VINCRISTINE SULFATE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BEAM THERAPY; CANCER PATIENT; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SALVAGE THERAPY;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARMUSTINE; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IFOSFAMIDE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MELPHALAN; MIDDLE AGED; PODOPHYLLOTOXIN; PREDNISONE; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS; VINCRISTINE;

EID: 39149123812     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2007.01020.x     Document Type: Article

References (37)

1. Gaynor ER, Fisher RI. Diffuse aggressive lymphomas in adults. In: Magrath IT, ed. The Non-Hodgkin's Lymphomas. London: Edward Arnold, 1992: 317 29.
2. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993 329: 987 94.
3. Conconi A, Zucca E, Roggero E, et al. Prognostic models for diffuse large B-cell lymphoma. Hematol Oncol 2000 18: 61 73.
4. Surbone A, Armitage JO, Gale RP. Autotransplantation in lymphoma: better therapy or healthier patients? Ann Intern Med 1991 114: 1059 60.
5. Shipp MA, Abeloff KH, Antman G, et al. International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury. J Clin Oncol 1999 17: 423 9.
6. Strehl J, Mey U, Glasmacher A, et al. High-dose chemotherapy followed by autologous stem cell transplantation as first-line therapy in aggressive non-Hodgkin's lymphoma: a meta-analysis. Haematologica 2003 88: 1304 15.
7. Greb A, Bohlius J, Trelle S, et al. High-dose chemotherapy with autologous stem cell support in first line treatment of aggressive non-Hodgkin lymphoma. Results of a comprehensive meta-analysis. Cancer Treat Rev 2007 33: 338 46.
8. Armitage J, Weisenburger D, Hutchins M, et al. Chemotherapy for diffuse large cell lymphoma - rapidly responding patients have more durable remissions. J Clin Oncol 1986 4: 160 4.
9. Haq R, Sawka CA, Franssen E, Berinstein NL. Significance of a partial or slow response to front-line chemotherapy in the management of intermediate-grade or high grade non-Hodgkin's lymphoma: a literature review. J Clin Oncol 1994 12: 1074 84.
10. Verdonck LF, Van Putten WLJ, Hagenbeek A, et al. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl J Med 1995 332: 1045 51.
11. Martelli M, Vignetti M, Zinzani PL, et al. High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized Italian multicenter study. J Clin Oncol 1996 14: 534 42.
12. van Imhoff GW, van der Holt B, Mackenzie MA, et al. Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-Hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40. J Clin Oncol 2005 23: 3793 801.
13. Kaplan WD, Jochelson MS, Herman TS, et al. Gallium-67 imaging: a predictor of residual tumor viability and clinical outcome in patients with diffuse large-cell lymphoma. J Clin Oncol 1990 8: 1966 70.
14. Front D, Bar-Shalom R, Mor M, et al. Aggressive non-Hodgkin lymphoma: early prediction of outcome with 67Ga scintigraphy. Radiology 2000 214: 253 7.
15. Bar-Shalom R, Yefremov N, Haim N, et al. Camera-based FDG PET and 67Ga SPECT in evaluation of lymphoma: comparative study. Radiology 2003 227: 353 60.
16. Juweid ME, Cheson B. Positron-emission tomography and assessment of cancer therapy. N Engl J Med 2006 354: 496 507.
17. Janicek M, Kaplan M, Neuberg D, et al. Early restaging gallium scans predict outcome in poor prognosis patients with aggressive non-Hodgkin's lymphoma treated with high-dose CHOP. J Clin Oncol 1997 15: 1631 7.
18. Israel O, Mor M, Epelbaum R, et al. Clinical pretreatment risk factors and Ga-67 scintigraphy early during treatment for prediction of outcome of patients with aggressive non-Hodgkin lymphoma. Cancer 2002 94: 873 8.
19. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994 84: 1361 92.
20. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committe meeting- Airlie House, Virginia, November 1997. J Clin Oncol 1999 17: 3835 49.
21. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999 17: 1244 53.
22. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958 53: 457 81.
23. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977 35: 1 39.
24. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002 346: 235 42.
25. Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 2004 104: 626 33.
26. Haioun C, Lepage E, Gisselbrecht C, et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol - a Groupe d'Etude des Lymphomes de l'Adulte Study. J Clin Oncol 2000 18: 3025 30.
27. Santini G, Salvagno L, Leoni P, et al. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group. J Clin Oncol 1998 16: 2796 802.
28. Gianni AM, Bregni M, Siena S, et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive non-Hodgkin's lymphoma. N Engl J Med 1997 336: 1290 7.
29. Milpied N, Deconink E, Gaillard F, et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem cell support. N Engl J Med 2004 350: 1287 95.
30. Kluin-Nelemans HC, Zagonel V, Anastasopoulou A, et al. Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study. J Natl Cancer Inst 2000 93: 22 30.
31. Kaiser U, Uebelacker I, Abel U, et al. Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma. J Clin Oncol 2002 20: 4413 9.
32. Gisselbrecht C, Lepage E, Molina T, et al. Shortened first-line high-dose chemotherapy for patients with poor-risk aggressive lymphoma. J Clin Oncol 2002 20: 2472 9.
33. Glass B, Kloess M, Bentz M, et al. Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma. Blood 2006 107: 3058 64.
34. Stewart DA, Bahlis N, Valentine K, et al. Upfront double high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 2006 107: 4623 7.
35. Canellos GM. CHOP may have been part of the beginning but certainly not the end: issues in risk-related therapy of large cell lymphoma. J Clin Oncol 1997 15: 1713 6.
36. Haioun C, Itti E, Rahmouni A, et al. [18F]fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 2005 106: 1376 81.
37. Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognosis Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007 109: 1857 61.